Collegium Pharmaceutical (COLL) PT Lowered to $26 at Needham & Company
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St futures gain on tech rebound, Middle East peace hopes
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil falls 1% as traders digest escalation in US-Iran strikes
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
Collegium Reports Third Quarter Fiscal 2021 Results
November 4, 2021 4:02 PM EDT- Board of Directors Has Authorized $25 Million Accelerated Share Repurchase Program -
- Net Income of $8.0 Million and Adjusted EBITDA of $37.3 Million -
- Full-Year 2021 Guidance Updated -
- Conference Call Scheduled for Today at 4:30 p.m. ET -
STOUGHTON, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being... More
